Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)

Journal of Hepatology

Volumn 58, Issue 3, 2013, Pages 445-451

  Lenz, Oliver ^a   Vijgen, Leen ^a   Berke, Jan Martin ^a   Cummings, Maxwell D ^b   Fevery, Bart ^a   Peeters, Monika ^a   Smedt, Goedele De ^a   Moreno, Christophe ^c   Picchio, Gaston ^d  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

HCV NS3 4A protease inhibitor; Hepatitis C; Non genotype 1; Polymorphism; TMC435 monotherapy; Virologic response

Indexed keywords

SIMEPREVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; REPLICON; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MUTATION; POLYMORPHISM, GENETIC; RNA, VIRAL; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84874105854     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.10.028     Document Type: Article

References (31)

1. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
2. P. Simmonds, J. Bukh, C. Combet, G. Deléage, N. Enomoto, and S. Feinstone Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 42 2005 962 973
3. N. Antaki, A. Craxi, S. Kamal, R. Moucari, S. Van der Merwe, and S. Haffar The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report Liver Int 30 2010 342 355
4. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
5. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
6. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
7. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
8. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
9. W.P. Hofmann, and S. Zeuzem A new standard of care for the treatment of chronic HCV infection Nat Rev Gastroenterol Hepatol 8 2011 257 264
10. Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2A and ribavirin in treatment-naive genotype 4 HCV patients. Poster Presented at the 44th annual meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, 22 April, 2009.
11. I. Imhof, and P. Simmonds Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191) Hepatology 53 2011 1090 1099
12. G.R. Foster, C. Hézode, J.P. Bronowicki, G. Carosi, O. Weiland, and L. Verlinden Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 2011 881 889
13. T. Wakita HCV research and anti-HCV discovery: toward the next generation Adv Drug Deliv Rev 59 2007 1196 1199
14. J.M. Gottwein, T.K. Scheel, T.B. Jensen, L. Ghanem, and J. Bukh Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses Gastroenterology 141 2011 1067 1079
15. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds RD, Hindes R, et al. Once Daily PSI-7977 plus RBV: pegylated interferon-Alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 (abstract 34). In: American Association for the Study of Liver Disease (AASLD), San Francisco, CA, USA, 4-8 November, 2011.
16. F.X. Lopez-Labrador, A. Moya, and F. Gonzalez-Candelas Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates Antivir Ther 13 2008 481 494
17. D. Lamarre, P.C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, and P. Bonneau An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186 189
18. M. Reiser, H. Hinrichsen, Y. Benhamou, H.W. Reesink, H. Wedemeyer, and C. Avendano Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C Hepatology 41 2005 832 835
19. D. Thibeault, C. Bousquet, R. Gingras, L. Lagacé, R. Maurice, and P.W. White Sensitivity of NS3 serine protease from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061 J Virol 78 2004 7352 7359
20. X. Tong, Z. Guo, J. Wright-Minogue, E. Xia, A. Prongay, and V. Madison Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors Biochemistry 45 2006 1353 1361
21. Silva M, Kasserra C, Gupta S, Treitel M, Hughes E, O'Mara E. antiviral activity of boceprevir monotherapy intreatment-naive subjects with chronic hepatitis c genotype 2/3 (abstract). In: 21st Conference of the Asian Pacific Association for the Study of the Liver, Bangkok, Thailand, February 17-20, 2011.
22. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: final analysis of the PILLAR phase IIb study (abstract). In: American association for the Study of Liver Disease (AASLD), San Francisco, CA, USA, 4-8 November, 2011.
23. M. Manns, H. Reesink, T. Berg, G. Dusheiko, R. Flisiak, and P. Marcellin Rapid viral response of once-daily TMC435 plus peginterferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial Antivir Ther 16 2011 1021 1033
24. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial (abstract A-455-0022-00482). In: Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, April 18-22, 2012.
25. C. Moreno, T. Berg, T. Tanwandee, S. Thongsawat, H. Van Vlierberghe, and S. Zeuzem Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a randomised, phase IIa, open-label study J Hepatol 56 2012 1247 1253
26. O. Lenz, T. Verbinnen, T.-I. Lin, L. Vijgen, M.D. Cummings, and J. Lindberg In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob Agents Chemother 54 2010 1878 1887
27. T.L. Kieffer, A.D. Kwong, and G.R. Picchio Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs) J Antimicrob Chemother 65 2010 202 212
28. K. Chayama, and C.N. Hayes Hepatitis C virus: how genetic variability affects pathobiology of disease J Gastroenterol Hepatol 26 Suppl 1 2011 83 95
29. M.D. Cummings, J. Lindberg, T.I. Lin, H. de Kock, O. Lenz, and E. Lilja Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target Angew Chem Int Ed Engl 49 2010 1652 1655
30. S. Vallet, F. Viron, C. Henquell, H. Le Guillou-Guillemette, G. Lagathu, and F. Abravanel NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5 Antivir Ther 16 2011 1093 1102
31. S. De Meyer, A. Ghys, G.R. Foster, M. Beaumont-Mauviel, B. van Baelen, and T.-I. Lin Analyses of genotype 2/3 HCV variants in patients treated with telaprevir in study C209 showed that the telaprevir resistance profile appears to be consistent across genotypes Antivir Ther 15 2010 (Abs A118)